ストックスクリーナーアプリを入手
27.86
6.45%
-1.92
アフターアワーズ：
28.25
0.39
+1.40%
前日終値:
$29.78
開ける：
$29.42
24時間の取引高:
1.31M
Relative Volume:
0.88
時価総額：
$2.20B
収益：
-
当期純損益:
$-119.67M
株価収益率:
-10.21
EPS:
-2.73
ネットキャッシュフロー:
$-97.30M
1週間 パフォーマンス:
-1.24%
1か月 パフォーマンス:
-15.52%
6か月 パフォーマンス:
+106.22%
1年 パフォーマンス:
+162.09%
1日の値動き範囲:
$27.80
$29.69
1週間の範囲:
$27.80
$32.21
52週間の値動き範囲:
$8.241
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
27.86 | 2.36B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 2,171 Shares - MarketBeat
Biotech Mineralys offers 4-year stock awards to new hires - Stock Titan
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Candriam S.C.A. - MarketBeat
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Exploring a 60% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Mineralys Therapeutics Sees Unusually Large Options Volume (NASDAQ:MLYS) - MarketBeat
Panic Selling: How sensitive is Mineralys Therapeutics Inc to inflationJuly 2025 Update & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Mineralys Therapeutics (MLYS) to Release Earnings on Wednesday - MarketBeat
Profit Review: How sensitive is Mineralys Therapeutics Inc to inflation2025 Momentum Check & Safe Entry Trade Reports - baoquankhu1.vn
Mineralys Therapeutics Reports Positive Phase 2 Trial Results for Lorundrostat in Hypertension and CKD - MSN
Mineralys Therapeutics (MLYS) Files Lorundrostat NDA Following Positive Clinical Milestones - Finviz
11 Best High Short Interest Stocks With Biggest Upside Potential - Insider Monkey
Mineralys Awards New Hire Stock Option as Hypertension Pipeline Advances - MSN
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Uncovering a 53.98% Potential Upside in Biotech - DirectorsTalk Interviews
What is HC Wainwright's Forecast for MLYS FY2030 Earnings? - MarketBeat
Insider Trends: How sensitive is Mineralys Therapeutics Inc to inflationWeekly Trade Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Aug EndMonth: Will CMPS benefit from rate cutsJuly 2025 Pullbacks & AI Powered Market Entry Ideas - baoquankhu1.vn
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Avoiding Lag: Real-Time Signals in (MLYS) Movement - Stock Traders Daily
Mineralys Therapeutics Inc call volume above normal and directionally bullish - TipRanks
Mineralys Therapeutics’ Earnings Call Highlights Positive Outlook - MSN
Relative Strength Alert For Mineralys Therapeutics - Nasdaq
Rodman sells Mineralys (MLYS) shares for $13,353 - Investing.com
Rodman sells Mineralys (MLYS) shares for $13,353 By Investing.com - Investing.com Nigeria
David Malcom Rodman Sells 416 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Fed Watch: What is Mineralys Therapeutics Incs revenue forecast2025 Market Overview & Smart Swing Trading Alerts - baoquankhu1.vn
Activity Recap: Is EKSO a potential multi baggerAnalyst Upgrade & Fast Moving Stock Watchlists - baoquankhu1.vn
Are Mineralys Therapeutics’ (MLYS) Executive Stock Plans Aligned With Lorundrostat’s Emerging Investment Story? - Sahm
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 7,709 Shares of Stock - MarketBeat
David Malcom Rodman Sells 11,367 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock - MarketBeat
Sell Signal: Is Mineralys Therapeutics Inc. part of any major index2025 Earnings Impact & Free High Return Stock Watch Alerts - baoquankhu1.vn
Mineralys Therapeutics CEO Congleton sells $529k in MLYS stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (NASDAQ:MLYS) CEO Sells $529,618.32 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock By Investing.com - Investing.com Canada
Mineralys Therapeutics MLYS officer sells $277k in stock By Investing.com - Investing.com South Africa
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $72,195.90 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $205,167.36 in Stock - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) CFO Sells $345,762.12 in Stock - MarketBeat
Levy, Mineralys Therapeutics CFO, sells $345k in MLYS stock - Investing.com
Mineralys Therapeutics MLYS officer sells $277k in stock - Investing.com
Buybacks Report: Will Mineralys Therapeutics Inc outperform tech stocksQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Patterns Watch: Whats Mineralys Therapeutics Incs historical returnJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Mineralys Targets Sleep Apnea and Hypertension With Lorundrostat: What Investors Should Watch - TipRanks
Mineralys Therapeutics, Inc. (MLYS) Stock Analysis: Unveiling a 54% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Discipline and Rules-Based Execution in MLYS Response - Stock Traders Daily
Trend Recap: Whats the RSI of Mineralys Therapeutics Inc stockJuly 2025 PostEarnings & Reliable Breakout Forecasts - baoquankhu1.vn
Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - ADVFN
Will Mineralys Therapeutics Inc. stock benefit from AI adoptionJuly 2025 Outlook & Risk Adjusted Buy/Sell Alerts - Улправда
Mineralys Therapeutics (MLYS) Stock Analysis Report | Financials & Insights - Benzinga España
Can Mineralys Therapeutics Inc. stock attract ESG capital inflowsEarnings Risk Summary & Weekly Breakout Watchlists - ulpravda.ru
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
Mineralys Therapeutics Inc (MLYS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rodman David Malcom | Chief Medical Officer |
Feb 09 '26 |
Sale |
30.21 |
2,171 |
65,586 |
50,437 |
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):